Twitxy Saved

Rick Bright

Verified account This account is verified. Learn more

@RickABright

Practical, Innovative, Hyper-focused on saving lives. Immunologist, Virologist, Pandemic Nemesis. Posts are mine.
Washington, DC Joined January 2017
3K Following 49K Followers 11K Posts

Latest posts 5

Rick Bright Verified account @RickABright
You nailed it @KatherineEban. And it wasn’t only @USDA @USDA_APHIS that drug their feet in the Biden Admin. @HHSGov agencies were slow to take action, share data, & test milk products or exposed workers. The entire response was slow, bare minimum, lacked transparency; hugely missed opportunity to build trust & sharpen pandemic readiness.

It’s no wonder the virus continues to circulate, mutate, & infect a broader circle of mammals across the U.S.

Modern pandemic readiness should be prioritized & funded urgently.
Katherine Eban @KatherineEban Oct 26
In 2024, I investigated why Biden Admin had slow-walked response to #H5N1 outbreak in dairy cows. The answer: @USDA let farmers not test cows, at dairy lobby's behest.
vanityfair.com/news/story/ins…

Strong 🧵on evolution of H5N1 risks: "This should have ended 2 years ago." 👇
View quoted post on X
5 replies 40 reposts 131 likes 6.3K views View on X
Rick Bright Verified account @RickABright
Leadership & Compassion
@DollyParton
Gavi, the Vaccine Alliance Verified account @gavi Aug 26
“Don’t be such a chicken squat. Get out there and get your shot.” -- Dolly Parton

Dolly Parton didn't just use her voice to encourage vaccination, she helped support the science behind it.

In April 2020, Dolly donated US$1 million to Vanderbilt University Medical Center for COVID-19 research, creating the Dolly Parton COVID-19 Research Fund. The fund supported researchers involved in the early testing of Moderna’s mRNA vaccine.

Then, in March 2021, she rolled up her own sleeve at Vanderbilt to receive the Moderna vaccine herself, using the moment to encourage others to get vaccinated too.

Today we remember Dolly not only for the joy she brought to millions, but for the role she played in advancing vaccine research and encouraging others to get protected.
View quoted post on X
4 replies 15 reposts 123 likes 4K views View on X
Rick Bright Verified account @RickABright
This is a very important and very concerning finding.
K-in-CT 😷😷😷 Verified account @KinCONN Aug 24
#H5N1

➡️ Live H5N1 Was Isolated from Fetal Bovine Serum in a Finding That Puts Laboratory Biosafety Under New Scrutiny

- Researchers at Cornell University ➡️ isolated live, infectious H5N1 avian influenza virus from ➡️ a commercial lot of fetal bovine serum, ➡️ the growth supplement used in cell culture laboratories worldwide, in a report published in the August issue of the CDC journal Emerging Infectious Diseases.

- The finding matters to a specific audience, and it is worth stating plainly who that is. This is a laboratory biosafety and manufacturing quality-control story, not a consumer exposure story. No pasteurized dairy product, retail meat item, or medical treatment is implicated. The people whose practices may change are diagnosticians, cell culture technicians, biomanufacturing staff, and the institutional biosafety committees that write their protocols.

- The detection also carries one immediately reassuring result. Heating the serum to 56 degrees Celsius for 30 minutes, a step already built into many commercial serum products and lab protocols, inactivated the virus in the authors' experiments.

- Routine Screening at Cornell Caught the Contaminated Lot

- The lot arrived at the Virology Laboratory of the Cornell Animal Health Diagnostic Center in February 2025 for routine extraneous agents testing, a screening requirement under federal regulations governing biological products of animal origin. It was not submitted because anyone suspected contamination.

- ➡️ Sequencing identified the virus as highly pathogenic avian influenza A(H5N1) clade 2.3.4.4b, genotype B3.13, the lineage that has been circulating in U.S. dairy cattle since March 2024. As of mid-December 2025, more than 1,084 herds in 19 states had been affected, with most concentrated in California.

- The ➡️ tested lot was a pool of samples collected in five states: Pennsylvania, Kansas, Nebraska, South Carolina, and California. That detail is the load-bearing one for anyone assessing risk in their own supply chain, and it is addressed below.

- Serum Is a Pooled Product, and That Matters

- Fetal bovine serum is collected from bovine fetuses at slaughterhouses and is, in the paper's own framing, the most frequently used growth supplement in cell culture media. It is commonly added to basal media at concentrations of about 5-10% and supports a wide range of cell types in academic research, pharmaceutical development, and biomanufacturing.

- Because it is pooled from many animals, a single infected donor can contribute a large amount that is subsequently widely distributed. ➡️ The Cornell team followed the positive lot with broader testing, screening individual serum samples collected at slaughterhouses in California and Texas, 384 from each state. ➡️ Of those 768 samples, one tested positive by real-time reverse transcription PCR, at a cycle threshold of 35, indicating a low viral load.

- ➡️ The authors interpret that pattern as consistent with sporadic viremia in infected lactating dairy cattle, allowing the virus to reach tissues beyond the udder, including, on rare occasions, the fetus. Follow-up testing of 13 additional bottles from the same original lot, eight of them not heat-inactivated and five heat-inactivated, is documented in a summary table accompanying the paper, using virus isolation in two cell lines, embryonated eggs, and PCR. Detection was infrequent even by PCR, and attempts to confirm virus isolation at USDA's National Veterinary Services Laboratories were not successful, which the authors take as evidence of very low viral loads in the pooled lot.

- Heat Treatment Cleared the Virus in Laboratory Tests

- The inactivation experiment is the part with an actionable conclusion. Serum aliquots were spiked with bovine H5N1 at high titer and heated. The authors report that ➡️ heating at 56 degrees Celsius for 30 minutes inactivated the virus, and they conclude that although finding a zoonotic virus in serum raises biosafety concerns for diagnostic testing of bovine serum and for laboratory procedures using it, ➡️ "heat treatment of FBS seems to be efficient in inactivating the virus" and could serve as a safety precaution.

- That temperature and duration are not novel. Commercial suppliers, including ATCC, publish 56 degrees for 30 minutes as the standard heat-inactivation protocol, and heat-inactivated serum is sold as a distinct product line. The complication is that ➡️ heat inactivation is not a universal practice because suppliers caution that it is unnecessary for many cell lines and can degrade heat-labile growth factors that some cells require.

- The result also aligns with earlier work. Heat inactivation of H5N1 in raw cow's milk was examined in a report in the New England Journal of Medicine, part of a broader body of research into how thermal treatment affects this virus in bovine-origin material.

= Consumers Are Not the Audience for This Finding

- Several limitations go hand in hand with the headline result. This is a single documented lot, identified through routine surveillance rather than through any adverse event. No laboratory-acquired infection has been reported in connection with it. The authors note that their findings and conclusions do not necessarily reflect the official positions of the agencies involved, and that one co-author is affiliated with USDA's Animal and Plant Health Inspection Service.

- The paper does not establish how often serum lots are contaminated because it was not designed to. Nor does it demonstrate that anyone has been infected through this route. It documents that a live virus survived in a commercial biological product and that a widely available treatment step neutralized it under laboratory conditions.

- What laboratories and biomanufacturers may reasonably reconsider is whether their current serum sourcing, screening, and heat-treatment decisions account for a pathogen that was not circulating in U.S. cattle three years ago. Institutional biosafety committees, not individual bench scientists, are typically the right level for that review. ➡️ Facilities working with bovine-origin material should confirm what their supplier tests for and whether their lots are heat-inactivated.

= The broader surveillance question remains open. Continued monitoring of H5N1 in dairy cattle and of the animal-origin products the herds feed into is tracked through the CDC journal's influenza research collection. ➡️ Whether contamination of serum proves to be rare or more common than a single lot suggests will depend on testing that has not yet been reported.

By Cole Mercer
medicaldaily.com/h5n1-fetal-bov…
View quoted post on X
10 replies 57 reposts 259 likes 29K views View on X
Rick Bright Verified account @RickABright
Science moves forward

Less than a year ago, I argued in @nytopinion that mRNA technology represented far more than a COVID vaccine—it's a platform for responding to future biological threats

Yesterday's FDA approval of the first mRNA influenza vaccine is another important step in that journey

NYT:
nytimes.com/2025/08/18/opi…
Perspective:
doi.org/10.3390/vaccin…
@nytimes @Vaccines_MDPI
www.nytimes.com Opinion | America Is Abandoning One of the Greatest Medical Breakthroughs (Published 2025) Giving up on mRNA is a dangerous decision.
0 replies 3 reposts 30 likes 2.8K views View on X
Rick Bright Verified account @RickABright
Competent reform also requires regular leadership renewal, fresh external perspectives, and governance structures that reward mission impact, transparency, and public trust.

NIAID’s next chapter should strengthen discovery, accelerate translation, modernize clinical trials, and ensure that high-risk research is overseen with independence, rigor, and accountability.
Dr Steven Quay Verified account @quay_dr Jul 6
As we enter the second half of 2026, I believe the next phase for NIAID should be competent reform:

stronger translational science,
better clinical trials,
faster therapeutics,
transparent governance of risky pathogen research,
and a renewed commitment to public trust.
View quoted post on X